ストックスクリーナーアプリを入手
9.365
3.60%
0.325
プレマーケット:
9.48
0.115
+1.23%
Syndax Pharmaceuticals Inc (SNDX) 最新ニュース
Learn to Evaluate (SNDX) using the Charts - news.stocktradersdaily.com
Syndax Pharmaceuticals’ SWOT analysis: revuforj launch boosts aml treatment stock - Investing.com
Syndax Pharmaceuticals' SWOT analysis: revuforj launch boosts aml treatment stock - Investing.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.7%What's Next? - MarketBeat
Assenagon Asset Management S.A. Lowers Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax reports publication of revumenib data from BEAT AML trial - Yahoo Finance
SNDX Trial Data Shows Promising Results in AML Treatment | SNDX Stock News - GuruFocus
Syndax Presents New Revuforj® (revumenib) Data in - GlobeNewswire
Syndax Announces Publication of Revumenib Data from the BEAT AML - GuruFocus
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025 - The Manila Times
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025 | SNDX Stock News - GuruFocus
Syndax Announces Publication of Revumenib Data from the - GlobeNewswire
Clinical Trial: New AML Drug Achieves 100% MRD Negativity, Doubles Survival vs Standard Care - Stock Titan
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of ... - Eagle-Tribune
Syndax Pharma releases new data from its AUGMENT-101 trial of Revuforj - The Pharma Letter
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refra - GuruFocus
SNDX: New Data Revealed from Syndax's AUGMENT-101 Trial | SNDX Stock News - GuruFocus
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 | SNDX Stock News - GuruFocus
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 - The Manila Times
Syndax Pharmaceuticals at Goldman Sachs Conference: Strategic Growth and Profitability - Investing.com Canada
Transcript : Syndax Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - MarketScreener
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 32,653 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Ameriprise Financial Inc. - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High? - MSN
Syndax Pharmaceuticals at Jefferies Conference: Strategic Growth and Expansion By Investing.com - Investing.com Canada
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Li - GuruFocus
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Ameriprise Financial Inc. Has $423,000 Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Bank of America Corp DE Sells 546,799 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Long Term Trading Analysis for (SNDX) - news.stocktradersdaily.com
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Nuveen Asset Management LLC - MarketBeat
Voloridge Investment Management LLC Acquires Shares of 79,071 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Wellington Management Group LLP Has $55.98 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading 4.9% HigherShould You Buy? - MarketBeat
84,998 Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Purchased by Polar Asset Management Partners Inc. - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Bank of America Corp DE - Defense World
Millennium Management LLC Lowers Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Brokerages Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Target Price at $35.91 - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Two Sigma Investments LP - MarketBeat
Syndax Announces Participation in June Investor Conferences | SN - GuruFocus
Syndax Announces Participation in June Investor Conferences - The Manila Times
0.78%
0.23%
大文字化:
|
ボリューム (24 時間):